resTORbio Announces Science Translational Medicine Publication of Phase 2a Data Showing Improvement in Immune Function and Decreased Infection Rates in People Aged 65 Years and Older
11 juil. 2018 14h07 HE
|
resTORbio, Inc.
resTORbio’s TORC1 inhibitors enhanced the function of the aging immune system and were associated with a statistically significant decrease in the incidence of all infections, including respiratory...
resTORbio Announces Appointment of Kerry Russell, M.D., Ph.D., as Vice President of Clinical Development
12 juin 2018 08h00 HE
|
resTORbio, Inc.
BOSTON, June 12, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC) today announced that Kerry Russell, M.D., Ph.D., has joined the company as its Vice President of Clinical Development, a newly...
resTORbio to Present at the Jefferies 2018 Global Healthcare Conference
01 juin 2018 08h00 HE
|
resTORbio, Inc.
BOSTON, June 01, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and...
resTORbio to Host Key Opinion Leader Symposium on TORC1 Inhibition
22 mai 2018 16h30 HE
|
resTORbio, Inc.
BOSTON, May 22, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and...
resTORbio Reports First Quarter 2018 Financial Results
10 mai 2018 16h01 HE
|
resTORbio, Inc.
Last patient dosed in Phase 2b trial; topline data now expected in third quarter of 2018 BOSTON, May 10, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical...
resTORbio to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
09 mai 2018 16h05 HE
|
resTORbio, Inc.
BOSTON, May 09, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and...
resTORbio Completes Dosing of Patients in Phase 2b Study to Reduce the Incidence of Respiratory Tract Infections in the Elderly
09 mai 2018 08h30 HE
|
resTORbio, Inc.
BOSTON, May 09, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and...
resTORbio to Present at the Deutsche Bank 43rd Annual Health Care Conference
01 mai 2018 16h05 HE
|
resTORbio, Inc.
BOSTON, May 01, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and...
resTORbio Reports Fourth Quarter and Full Year 2017 Financial Results
29 mars 2018 16h05 HE
|
resTORbio, Inc.
BOSTON, March 29, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and...
resTORbio Announces Formation of Clinical Advisory Board
19 mars 2018 08h00 HE
|
resTORbio, Inc.
Esteemed Experts Engaged as Company Advances Clinical Development Program Phase 2b Data for Lead Program Expected in the Second Half of 2018 BOSTON, March 19, 2018 (GLOBE NEWSWIRE) -- resTORbio,...